1. Home
  2. GBIO vs TEAF Comparison

GBIO vs TEAF Comparison

Compare GBIO & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • TEAF
  • Stock Information
  • Founded
  • GBIO 2016
  • TEAF 2017
  • Country
  • GBIO United States
  • TEAF United States
  • Employees
  • GBIO N/A
  • TEAF N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • TEAF Trusts Except Educational Religious and Charitable
  • Sector
  • GBIO Health Care
  • TEAF Finance
  • Exchange
  • GBIO Nasdaq
  • TEAF Nasdaq
  • Market Cap
  • GBIO 145.5M
  • TEAF 165.2M
  • IPO Year
  • GBIO 2020
  • TEAF N/A
  • Fundamental
  • Price
  • GBIO $2.17
  • TEAF $12.78
  • Analyst Decision
  • GBIO Buy
  • TEAF
  • Analyst Count
  • GBIO 4
  • TEAF 0
  • Target Price
  • GBIO $7.50
  • TEAF N/A
  • AVG Volume (30 Days)
  • GBIO 61.6K
  • TEAF 56.1K
  • Earning Date
  • GBIO 08-07-2024
  • TEAF 01-01-0001
  • Dividend Yield
  • GBIO N/A
  • TEAF 9.20%
  • EPS Growth
  • GBIO N/A
  • TEAF N/A
  • EPS
  • GBIO N/A
  • TEAF N/A
  • Revenue
  • GBIO $13,174,000.00
  • TEAF N/A
  • Revenue This Year
  • GBIO $99.36
  • TEAF N/A
  • Revenue Next Year
  • GBIO N/A
  • TEAF N/A
  • P/E Ratio
  • GBIO N/A
  • TEAF N/A
  • Revenue Growth
  • GBIO 1397.05
  • TEAF N/A
  • 52 Week Low
  • GBIO $0.86
  • TEAF $11.11
  • 52 Week High
  • GBIO $4.83
  • TEAF $13.30
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 39.60
  • TEAF 71.78
  • Support Level
  • GBIO $2.13
  • TEAF $12.18
  • Resistance Level
  • GBIO $2.49
  • TEAF $12.37
  • Average True Range (ATR)
  • GBIO 0.22
  • TEAF 0.12
  • MACD
  • GBIO -0.04
  • TEAF 0.04
  • Stochastic Oscillator
  • GBIO 8.64
  • TEAF 100.00

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About TEAF Ecofin Sustainable and Social Impact Term Fund

Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.

Share on Social Networks: